medRxiv
August 24, 2023
Subha Subramanian, Demetrius Perry, Caterina Gratton et al.
14 citations
preprint
Psilocybin disrupts connectivity across cortical networks and subcortical structures, producing more than three-fold greater acute changes in functional networks than methylphenidate. These changes are driven by desynchronization of brain activity across spatial scales, strongest in the default mode network (DMN), which is connected to the anterior hippocampus and thought to create our sense of self. Performing a perceptual task reduces psilocybin-induced network changes, suggesting a neurobiological basis for grounding during psychedelic therapy. Psilocybin induces a persistent decrease in functional connectivity between the anterior hippocampus and cortex (and DMN in particular), lasting for weeks but normalizing after six months. This persistent suppression of hippocampal-DMN connectivity represents a candidate neuroanatomical and mechanistic correlate for psilocybin's pro-plasticity and anti-depressant effects.
Scientific Data
June 5, 2025
Subha Subramanian, Travis Rick Renau, Demetrius Perry et al.
4 citations
A psychedelic drug, psilocybin, and a comparison drug, methylphenidate, produce distinct acute and persistent changes in brain networks measurable with precision functional mapping, a technique that improves signal detection by repeatedly scanning individuals. Seven healthy adults underwent extensive baseline brain imaging, imaging shortly after drug intake, and follow-up scans for up to two weeks. Four participants repeated the psilocybin protocol months later. The dataset includes resting-state and task-based functional MRI, structural scans, and subjective experience reports. The authors release this resource to help researchers study how psilocybin and methylphenidate alter brain network organization over time.
Nat Hum Behav
February 24, 2025
Ginger E. Nicol, Danielle R. Adams, Eric J. Lenze et al.
4 citations
Psychedelic-assisted therapy (PAT) combines medication with psychotherapy, but many questions remain about how it works, for whom, and in what context. To avoid the typical 17-year delay between research and clinical practice, implementation science can help by simultaneously studying safety, effectiveness, and real-world delivery. Methods like sequential multiple assignment randomized trials (SMART), hybrid study designs, and fidelity measurement can speed implementation while maintaining quality and safety. Substantial changes to regulations, training, and access are needed to accommodate this multimodal therapy outside research settings. The authors advocate proceeding with accelerated caution.